From: Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis
Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of Comments the evidence (GRADE) | |
---|---|---|---|---|---|
Assumed risk | Corresponding risk | ||||
Control | ribavirin | ||||
Mortality (RCT) Follow-up: mean 8 weeks | 56 per 1000 | 63 per 1000 (16 to 242) | RR 1.13 (0.29 to 4.32) | 136 (1 study) | ⊕⊕⊖⊖ low 1,2 |
Mortality (Observational studies) Follow-up: 1-12 months | 254 per 1000 | 142 per 1000 (89 to 229) | RR 0.56 (0.35 to 0.9) | 955 (11 studies) | ⊕⊖⊖⊖ Very low 3,4,5,6 |
Length of Hospital stay (RCT) Days in hospital Follow-up: mean 8 weeks | The mean length of hospital stay (rct) in the control groups was 6.3 days | The mean Length of hospital stay (RCT) in the intervention groups was 0.21 standard deviations lower (0.55 lower to 0.12 higher) | 136 (1 study) | ⊕⊖⊖⊖ very low 1,2 | |
Length of Hospital Stay (Observational studies) days in hospital Follow-up: mean 4-24 months | The mean length of hospital stay (observational studies) in the control groups was 6.4 days | The mean Length of hospital stay (Observational studies) in the intervention groups was 0.60 standard deviations lower (1.21 lower to 0 higher) | 303 (3 studies) | ⊕⊖⊖⊖ Very low 3,5,6,7 |